Neurocrine Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Neurocrine Bio. (NBIX) PT Lowered to $105 at Cowen
February 6, 2019 7:54 AM ESTCowen analyst Phil Nadeau lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $105.00 (from $115.00) while maintaining a Outperform rating.
The analyst commented, "NBIX reported Q4 Ingrezza sales of $130.3MM, consistent with its January pre-announcement. Results from NBI-74788's Ph. IIa in CAH... More
Neurocrine Biosciences (NBIX) Tops Q4 EPS by 2c
February 5, 2019 4:02 PM ESTNeurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $0.19, $0.02 better than the analyst estimate of $0.17. Revenue for the quarter came in at $131.5 million versus the consensus estimate of $129.85 million.
GUIDANCE:
Revenue milestones under the AbbVie agreement for 2019 are expected... More
